Kezar Life Sciences, Inc. (KZR)
- Previous Close
0.7895 - Open
0.7980 - Bid 0.7531 x 200
- Ask 0.8189 x 200
- Day's Range
0.7860 - 0.7980 - 52 Week Range
0.6700 - 3.1300 - Volume
7,516 - Avg. Volume
813,203 - Market Cap (intraday)
58.096M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3900 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
www.kezarlifesciences.comRecent News: KZR
Performance Overview: KZR
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KZR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KZR
Valuation Measures
Market Cap
57.48M
Enterprise Value
-104.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.20
Price/Book (mrq)
0.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.01%
Return on Equity (ttm)
-48.07%
Revenue (ttm)
7M
Net Income Avi to Common (ttm)
-101.33M
Diluted EPS (ttm)
-1.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
179.8M
Total Debt/Equity (mrq)
10.81%
Levered Free Cash Flow (ttm)
-46.65M
Research Analysis: KZR
Company Insights: KZR
KZR does not have Company Insights